<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01779557</url>
  </required_header>
  <id_info>
    <org_study_id>HR-PD-2012</org_study_id>
    <secondary_id>ChiCTR-TRC-13003001</secondary_id>
    <nct_id>NCT01779557</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness Evaluation of Two Kinds of Peritoneal Dialysate</brief_title>
  <acronym>SEED</acronym>
  <official_title>The Prospective, Randomized, Parallel, Controlled, Multi-center Clinical Study of Huaren Peritoneal Dialysate and Baxter Peritoneal Dialysate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the effectiveness and safety of Huaren Peritoneal Dialysate and&#xD;
      Baxter Peritoneal Dialysate, investigate the proper dialysis dose for Chinese CAPD patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, parallel, controlled, multi-center clinical study of&#xD;
      Huaren Peritoneal Dialysate and Baxter Peritoneal Dialysate.It aims to investigate the proper&#xD;
      dialysis dose for Chinese CAPD patients.At the same time,it can evaluate the effectiveness&#xD;
      and safety of Chinese product Huaren Peritoneal Dialysate and peritoneal dialysis product&#xD;
      Baxter Peritoneal Dialysate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival rate</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PD technique survival rate</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated glomerular filtration rate decline</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nutritional status</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life(SF-36)</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular events</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>increments of dialysis dose</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>medical costs</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dropout rate</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>AE, vital signs, laboratory tests</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>peritonitis</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>quality of products</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>allergy to PD fluids, bags and tubes</measure>
    <time_frame>1,2,3,4,5 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">750</enrollment>
  <condition>Kidney Failure,Chronic</condition>
  <arm_group>
    <arm_group_label>Huaren peritoneal dialysate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Huaren Peritoneal dialysate CAPD 3-5 times/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baxter Peritoneal Dialysate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Baxter Peritoneal dialysate CAPD 3-5 times/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Huaren Peritoneal Dialysate</intervention_name>
    <description>Huaren Peritoneal dialysate CAPD 3-5 times/d</description>
    <arm_group_label>Huaren peritoneal dialysate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baxter Peritoneal Dialysate</intervention_name>
    <description>Baxter Peritoneal dialysate CAPD 3-5 times/d</description>
    <arm_group_label>Baxter Peritoneal Dialysate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18, male or female&#xD;
&#xD;
          -  Patients with end stage renal diseases&#xD;
&#xD;
          -  Dialysis mode: CAPD&#xD;
&#xD;
          -  Dialysis duration:≥30 days and ≤6 months&#xD;
&#xD;
          -  Be capable of implementing home dialysis&#xD;
&#xD;
          -  Diabetic nephropathy, 3ml/min≤ residual renal GFR ≤15ml/min; other renal diseases,&#xD;
             3ml/min≤ residual renal GFR ≤10ml/min&#xD;
&#xD;
          -  Sign the written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute renal failure&#xD;
&#xD;
          -  Planing to receive kidney transplantation in 2 years&#xD;
&#xD;
          -  Hemodialysis&#xD;
&#xD;
          -  Exit site infection or tunnel infection&#xD;
&#xD;
          -  Presenting 2/3 of the following: a. abdominal pain, turbid ascites, with or without&#xD;
             fever; b. drainage fluid WBC&gt;100×106/L, neutrophil ratio&gt;50%; c.culture positive/ Gram&#xD;
             stain positive in drainage fluid;&#xD;
&#xD;
          -  Anti-HIV positive&#xD;
&#xD;
          -  Allergic to components of dialysate&#xD;
&#xD;
          -  Active, residual malignant tumor, or systemic infection, liver cirrhosis, severe&#xD;
             congestive heart failure, anemia（Hb&lt;80g/L）,malnutrition（Serum Alb&lt;28g/L）,refractory&#xD;
             hypertension&#xD;
&#xD;
          -  Identified peritoneal high transportation by peritoneal equilibration test (PET)&#xD;
&#xD;
          -  Extreme body shape (height&gt; 185cm or height &lt;145cm), obesity (BMI ≥ 33kg/m2)&#xD;
&#xD;
          -  Poor compliance&#xD;
&#xD;
          -  Pregnant or lactating, women of childbearing age do not agree to use effective&#xD;
             contraceptive measures during the trial&#xD;
&#xD;
          -  Has a history of alcoholism and drug abuse (defined as illegal drugs)&#xD;
&#xD;
          -  Any circumstances when patients are believed unsuitable for this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CHEN Xiangmei, yes</last_name>
    <role>Study Director</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.301hospital.com.cn/</url>
    <description>The official website of Chinese PLA General Hospital.</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 29, 2013</study_first_submitted>
  <study_first_submitted_qc>January 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2013</study_first_posted>
  <last_update_submitted>August 1, 2021</last_update_submitted>
  <last_update_submitted_qc>August 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Chen Xiangmei</investigator_full_name>
    <investigator_title>Professor, Chief physician, Academician of Chinese Academy of Engineering</investigator_title>
  </responsible_party>
  <keyword>CAPD</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>survival rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dialysis Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

